Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XOLMA: Omalizumab in Mastocytosis
NCT01333293Phase 3Completed
- Sponsor
- University of Zurich
- Start
- Sep 2011
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in mastocytosis, sponsored by University of Zurich. Started Sep 2011; status: completed.
02
Drugs
omalizumab
03
Conditions
mastocytosis
Beyond the preview
Go deeper on NCT01333293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01333293.